PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Addex Therapeutics Ltd (ADXN)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00654J1079
CUSIP00654J107
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$21.75M
EPS-$18.45
PE Ratio65.35
PEG Ratio1.75
Revenue (TTM)$1.65M
Gross Profit (TTM)$1.44M
EBITDA (TTM)-$9.98M
Year Range$5.00 - $27.90
Target Price$1,050.20
Short %0.05%
Short Ratio1.18

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Addex Therapeutics Ltd

Popular comparisons: ADXN vs. SPY

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Addex Therapeutics Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%100.00%200.00%300.00%NovemberDecember2024FebruaryMarchApril
149.30%
21.14%
ADXN (Addex Therapeutics Ltd)
Benchmark (^GSPC)

S&P 500

Returns By Period

Addex Therapeutics Ltd had a return of 157.02% year-to-date (YTD) and 3.67% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date157.02%6.33%
1 month31.84%-2.81%
6 months149.60%21.13%
1 year3.67%24.56%
5 years (annualized)N/A11.55%
10 years (annualized)N/A10.55%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202471.07%-8.12%34.60%
2023-17.71%-18.16%-11.76%9.01%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ADXN is 55, suggesting that the investment has average results relative to the market in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.

The Risk-Adjusted Performance Rank of ADXN is 5555
Addex Therapeutics Ltd(ADXN)
The Sharpe Ratio Rank of ADXN is 5252Sharpe Ratio Rank
The Sortino Ratio Rank of ADXN is 6161Sortino Ratio Rank
The Omega Ratio Rank of ADXN is 5959Omega Ratio Rank
The Calmar Ratio Rank of ADXN is 5353Calmar Ratio Rank
The Martin Ratio Rank of ADXN is 5050Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Addex Therapeutics Ltd (ADXN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ADXN
Sharpe ratio
The chart of Sharpe ratio for ADXN, currently valued at 0.07, compared to the broader market-2.00-1.000.001.002.003.000.07
Sortino ratio
The chart of Sortino ratio for ADXN, currently valued at 0.91, compared to the broader market-4.00-2.000.002.004.006.000.91
Omega ratio
The chart of Omega ratio for ADXN, currently valued at 1.11, compared to the broader market0.501.001.501.11
Calmar ratio
The chart of Calmar ratio for ADXN, currently valued at 0.08, compared to the broader market0.001.002.003.004.005.006.000.08
Martin ratio
The chart of Martin ratio for ADXN, currently valued at 0.15, compared to the broader market0.0010.0020.0030.000.15
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.91, compared to the broader market-2.00-1.000.001.002.003.001.91
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.77, compared to the broader market-4.00-2.000.002.004.006.002.77
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.501.001.501.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.46, compared to the broader market0.001.002.003.004.005.006.001.46
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.61, compared to the broader market0.0010.0020.0030.007.61

Sharpe Ratio

The current Addex Therapeutics Ltd Sharpe ratio is 0.07. A Sharpe ratio between 0 and 1.0 is considered sub-optimal.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
0.07
1.91
ADXN (Addex Therapeutics Ltd)
Benchmark (^GSPC)

Dividends

Dividend History


Addex Therapeutics Ltd doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-96.79%
-3.48%
ADXN (Addex Therapeutics Ltd)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Addex Therapeutics Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Addex Therapeutics Ltd was 98.94%, occurring on Dec 18, 2023. The portfolio has not yet recovered.

The current Addex Therapeutics Ltd drawdown is 96.79%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.94%Dec 28, 2020749Dec 18, 2023
-57.31%Jan 31, 202010Mar 23, 202044Aug 7, 202054
-53.38%Aug 10, 202058Nov 30, 202017Dec 24, 202075

Volatility

Volatility Chart

The current Addex Therapeutics Ltd volatility is 44.43%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%NovemberDecember2024FebruaryMarchApril
44.43%
3.59%
ADXN (Addex Therapeutics Ltd)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Addex Therapeutics Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items